M&A / Deals Lilly to acquire CrossBridge Bio for up to $300m Pharmaceutical TechnologyEli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.M&A / DealsRead full story pharminent April 15, 2026 Pharmaceutical Technology Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly to acquire CrossBridge Bio for up to $300mNext: FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
